Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Zezhong Liu, Wei Xu, Shuai Xia, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

mRNA-based therapeutics: powerful and versatile tools to combat diseases
Shugang Qin, Xiaoshan Tang, Yu‐Ting Chen, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 384
Antibodies and Vaccines Target RBD of SARS-CoV-2
Long Min, Qiu Sun
Frontiers in Molecular Biosciences (2021) Vol. 8
Open Access | Times Cited: 154
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
Qian He, Qunying Mao, Jialu Zhang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 111
Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates
Shuyu Shou, Menghui Liu, Yang Yang, et al.
Frontiers in Microbiology (2021) Vol. 12
Open Access | Times Cited: 108
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
Zezhong Liu, Jie Zhou, Wei Xu, et al.
Cell Research (2022) Vol. 32, Iss. 3, pp. 269-287
Open Access | Times Cited: 71
Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
Uri Elia, Srinivas Ramishetti, Ronit Rosenfeld, et al.
ACS Nano (2021) Vol. 15, Iss. 6, pp. 9627-9637
Closed Access | Times Cited: 79
SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury
Mengli Wu, Feng‐Liang Liu, Jing Sun, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 66
Animal models for SARS-CoV-2
Chung-Young Lee, Anice C. Lowen
Current Opinion in Virology (2021) Vol. 48, pp. 73-81
Open Access | Times Cited: 65
Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates
Konlavat Siriwattananon, Suwimon Manopwisedjaroen, Balamurugan Shanmugaraj, et al.
Frontiers in Plant Science (2021) Vol. 12
Open Access | Times Cited: 62
Impact of the SARS‐CoV‐2 virus on male reproductive health
Daniel E. Nassau, Jordan C. Best, Eliyahu Kresch, et al.
BJU International (2021) Vol. 129, Iss. 2, pp. 143-150
Open Access | Times Cited: 62
Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects
Jiaxin Zheng, Yingying Deng, Zhenyu Zhao, et al.
Cellular and Molecular Immunology (2021) Vol. 19, Iss. 2, pp. 150-157
Open Access | Times Cited: 62
The role of B cells in COVID-19 infection and vaccination
Shiru Chen, Fei Guan, Fabio Candotti, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 58
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang, Ying Lu, Yan‐Bo Zhao, et al.
Cell Research (2022) Vol. 32, Iss. 12, pp. 1068-1085
Open Access | Times Cited: 51
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
Shuai Xia, Lijue Wang, Fanke Jiao, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
Antonio Barreiro, Antoni Prenafeta, G. Bech-Sàbat, et al.
iScience (2023) Vol. 26, Iss. 3, pp. 106126-106126
Open Access | Times Cited: 21
Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD
Zezhong Liu, Jie Zhou, Weijie Wang, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101445-101445
Open Access | Times Cited: 10
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection
Zi‐Wei Ye, Shuofeng Yuan, Jasper Fuk‐Woo Chan, et al.
Emerging Microbes & Infections (2021) Vol. 10, Iss. 1, pp. 291-304
Open Access | Times Cited: 54
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Muhammad Umer Ashraf, Yeji Kim, Sunil Kumar, et al.
Vaccines (2021) Vol. 9, Iss. 2, pp. 171-171
Open Access | Times Cited: 53
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
Shuai Xia, Qiaoshuai Lan, Yun Zhu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 53
Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse
Yingying Du, Yuhua Xu, Feng Jin, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2280-2287
Open Access | Times Cited: 52
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
Hamid Motamedi, Marzie Mahdizade Ari, Shirin Dashtbin, et al.
International Immunopharmacology (2021) Vol. 96, pp. 107763-107763
Open Access | Times Cited: 49
Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems
Iuliia A. Merkuleva, Д. Н. Щербаков, M. B. Borgoyakova, et al.
Vaccines (2022) Vol. 10, Iss. 1, pp. 96-96
Open Access | Times Cited: 35
Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern
Jian Wang, Yu Wen, Shihao Zhou, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 3, pp. 2558-2570
Closed Access | Times Cited: 35
Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
Shan Su, Weihua Li, Shibo Jiang
Trends in Immunology (2022) Vol. 43, Iss. 3, pp. 170-172
Open Access | Times Cited: 31
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2
Yu Liang, Jing Zhang, Run Yu Yuan, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top